학술논문

Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cance
Document Type
Journal
Source
MOLECULAR CANCER THERAPEUTICS; DEC 2023, 22 12, 2p. Supplement: S
Subject
Language
English
ISSN
15388514